Lilly says drug slows Alzheimer's in patients with mild disease

July 22 (Reuters) - Patients with mild Alzheimer's disease who took Eli Lilly and Co's experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability, according to new Lilly data released on Wednesday.